OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hecht on the Investigation of XL092/Atezolizumab in MSS/MSI-L mCRC

February 1st 2023

J. Randolph (Randy) Hecht, MD, discusses the investigation of XL092 plus atezolizumab in patients with microsatellite stable/microsatellite instability–low metastatic colorectal cancer.

Dr. Hochster on Trastuzumab/Pertuzumab Vs Cetuximab/Irinotecan in HER2-Amplified mCRC

February 1st 2023

Howard S. Hochster, MD, discusses the evaluation of trastuzumab and pertuzumab vs cetuximab and irinotecan in HER2-amplified metastatic colorectal cancer.

Dr. Gupta on the Use of Platinum Plus Standard Neoadjuvant Chemotherapy in TNBC

January 31st 2023

Sudeep Gupta, MBBS, professor, medical oncology, Tata Memorial Hospital, Mumbai, discusses key efficacy and safety data from a phase 3 trial of platinum plus standard neoadjuvant chemotherapy in operable, locally advanced triple-negative breast cancer.

Dr. Chavez Mac Gregor on Key Results From SWOG S1207 in HR+/HER2- Breast Cancer

January 31st 2023

Mariana Chavez Mac Gregor, MD, MSC, discusses key efficacy and safety data from the phase 3 SWOG S1207 trial of everolimus in hormone receptor–positive, HER2-negative breast cancer.

Dr. King on Delays in Access to Germline Testing in Pancreatic Cancer

January 31st 2023

Daniel King, MD, PhD, discusses socioeconomic disparities causing delays in germline genetic testing for patients with pancreatic cancer.

Dr. Cohen on the Timing of ctDNA Testing in Resected Stage I-III CRC

January 31st 2023

Stacey A. Cohen, MD, discusses the investigation of the optimal timing to test for circulating tumor DNA to detect minimal residual disease following surgery in patients with stage I to III colorectal cancer.

Dr. Starr on the Characterization of POLE/POLD1 Mutations in Colorectal Adenocarcinoma

January 31st 2023

Jason Starr, DO, discusses the characterization of POLE/POLD1 mutations in colorectal adenocarcinoma.

Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine Neoplasms

January 31st 2023

Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.

Dr. Kishan on the MIRAGE Trial of MRI-Guided SBRT in Prostate Cancer

January 30th 2023

Amar U. Kishan, MD, discusses interim results from the phase 3 MIRAGE trial of magnetic resonance imaging–guided stereotactic body radiotherapy in prostate cancer.

Dr. Jakubowiak on Initial Efficacy Data From the ATLAS Trial in Multiple Myeloma

January 30th 2023

Andrzej Jakubowiak, MD, PhD, discusses initial efficacy results from the phase 3 ATLAS trial in multiple myeloma.

Dr. Morris on the Investigation of the Role of ctDNA in Stage II CRC

January 30th 2023

Van K. Morris, MD, discusses the evaluation of circulating tumor as a predictive biomarker for the use of adjuvant chemotherapy in patients with low-risk, stage II colon cancer.

Dr. Strickland on the Diagnosis of ESCC

January 30th 2023

Stephen A. Strickland, MD, MSCI, discusses a step-by-step approach for the diagnosis and workup of esophageal squamous cell carcinoma.

Dr. de Marinis on the PERLA Trial in Metastatic NSCLC

January 30th 2023

Filippo de Marinis, MD, discusses the goal of the phase 2 PERLA trial in metastatic nonsquamous non–small cell lung cancer, as well as significant results from a primary analysis of this study.

Dr. Phillips on the FDA Approval of Pirtobrutinib in MCL

January 27th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of pirtobrutinib in mantle cell lymphoma.

Dr. Schulte on the PRECISION 1 Trial of Nab-Sirolimus in TSC1/2-Mutated Solid Tumors

January 27th 2023

Brian Schulte, MD, discusses the ongoing phase 2 PRECISION 1 basket trial evaluating the use of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring TSC1/2 mutations.

Dr. Goodman on the Use of SBRT in Locally Advanced Pancreatic Cancer

January 27th 2023

Karyn A. Goodman, MD, MS, discusses key toxicity and efficacy data supporting the use of stereotactic body radiation therapy in locally advanced pancreatic cancer.

Dr. Hubbard on the Use of the PolyPEPI1018 Vaccine Plus Chemotherapy in Metastatic CRC

January 27th 2023

Joleen M. Hubbard, MD, discusses key survival data from the phase 1b study of the PolyPEPI1018 vaccine and the impact of these findings on continued investigations of this vaccine in metastatic colorectal cancer.

Dr. Palta on the Clinical Implications of the NRG/RTOG 1112 Trial in HCC

January 26th 2023

Manisha Palta, MD, discusses the clinical implications of the phase 3 NRG/RTOG 1112 trial in patients with locally advanced hepatocellular carcinoma.

Dr. Halmos on the Safety and Efficacy of Lurbinectedin in Second-line SCLC

January 26th 2023

Balazs Halmos, MD, discusses the safety and efficacy of lurbinectedin in the second-line setting for patients with small cell lung cancer.

Dr. George on Long-Term Data on Total Neoadjuvant Therapy in Rectal Cancer

January 26th 2023

Thomas J. George, MD, FACP, discusses long-term data from the phase 2 NRG-GI002 trial of total neoadjuvant therapy in locally advanced rectal cancer.